Qiagen partners with Tracer Biotechnologies to advance solid tumor MRD testing via QIAcuity. See how this impacts QGEN stock and oncology diagnostics.

Assays designed for integration into existing QIAcuity to support research, wastewater surveillance and analytical evaluation by qualified laboratories QIAGEN’s broader Sample to Insight portfolio includes kits for sample preparation and next-generation sequencing to support outbreak research workflows VENLO, Netherlands, & GERMANTOWN, Md.--(BUSINESS WIRE)--$QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak. The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater surveillance and other environmental monitoring settings. They were developed using publicly available genomic sequence information released during the outbreak response and are part of QIAGEN’s broader Sample to Insight portfolio supporting infectious disease research workflows. The assays target the nucleoprotein (NP) and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by QIAGEN. The assays are intended for research use only and are not intended for diagnostic procedures. The availability of these assays underscores the role of adaptable molecular technologies in supporting public health research infrastructure...

YouTube video by CERI & KRISP Centre Epidemic Response & Innovation

QIAGEN (NYSE:QGEN) announced expansions to its QIAcuity digital PCR ecosystem to support wider adoption in research and biopharma. New offerings include planned gene expression assays for human, mouse and rat, a high-multiplex RNA kit, expanded Cell and Gene Therapy quality-control assays, enhanced QIAcuity Software 3.5 and Hamilton-based automation.According to QIAGEN, QIAcuity has over 3,200 placements worldwide, 400+ multi-instrument customers and 1,100+ publications.

QIAGEN (NYSE:QGEN) announced two custom research-use-only QIAcuity digital PCR assays targeting Bundibugyo ebolavirus sequences linked to the current outbreak. These assays, designed for the QIAcuity system, focus on the virus’s NP and VP35 regions to support research, wastewater surveillance and environmental monitoring.Initial in silico analysis showed no mismatches with reviewed outbreak sequences. The assays are make-to-order via QIAGEN’s custom workflow and complement in-stock QIAseq sequencing panels and sample preparation kits within the broader Sample to Insight portfolio.

Groundbreaking partnership enables minimally invasive cancer monitoring using QIAcuity digital PCR platform. Discover how this changes tumor detection forever.

QIAGEN (NYSE: QGEN) has announced two strategic partnerships to expand its minimal residual disease (MRD) testing capabilities in oncology. The company partnered with Tracer Biotechnologies to develop blood-based MRD tests for solid tumors using QIAcuity digital PCR systems, and with Foresight Diagnostics to create a kit version of its CLARITY™ NGS assay for lymphoma. These partnerships aim to advance decentralized, non-invasive tools for cancer monitoring and personalized treatment decisions. The collaborations will support pharmaceutical companies' clinical trials and companion diagnostic development. QIAGEN's comprehensive MRD portfolio includes sample technologies, testing platforms, and digital insights solutions, with plans to launch an upgraded QIAsymphony Connect version in late 2025.

QIAGEN (NYSE:QGEN) reports strong preliminary Q1 2025 results, exceeding previous guidance. Net sales grew approximately 5% (+7% at constant exchange rates) to about $483 million, surpassing the outlook of 3% CER growth.The company's QuantiFERON latent TB test saw ~15% CER growth, while the QIAstat-Dx syndromic testing system advanced above 35% CER. The QIAcuity digital PCR system and QIAGEN Digital Insights both achieved high-single-digit CER gains. Sample technologies sales declined 1% CER due to cautious instrument spending among Life Sciences customers.QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to $2.35 CER from $2.28 CER, while maintaining its goal to improve adjusted operating income margin to above 30%. Q1 2025 adjusted diluted EPS is expected to be at least $0.55 CER, exceeding the previous outlook of $0.50 CER.